← All trials
NCT03707041
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 11, 2018
- Primary completion
- May 27, 2019
- Completion date
- May 27, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 32
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medicines for Malaria VentureLead sponsor
- Washington University in St. LouisCollaborator
- SGS Life SciencesOverall official - principal investigator
- SGS Life SciencesCollaborator
- Sanaria Inc.Collaborator
- Institute of Tropical Medicine, BelgiumCollaborator
- Swiss BioQuant A.G., SwitzerlandCollaborator
- PrimeVigilance LTDCollaborator
- Medicines for Malaria VentureStudy director
- FGK Clinical Research GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.